Explore ViiV Healthcare
Medicines in Development
ViiV Healthcare is committed to developing new medicines for HIV to reduce its impact on the more than 36 million people living with the virus.1 Our scientists and researchers continue to work to identify new ways to lessen the burden not only of the disease, but also of daily treatment of HIV.
Clinical development pipeline
|dolutegravir + lamivudine
||INSTI + NRTI
|LA cabotegravir + LA rilpivirine*
(for intramuscular injection)
|INSTI + NNRTI
*in collaboration with Janssen
INSTI = integrase strand transfer inhibitor; LA = long-acting; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside transcriptase inhibitor; STR = single-tablet regimen
1. UNAIDS. Global HIV & AIDS Statistics — 2018 Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet. Last Accessed October 2018.
Website images are not intended to imply that the models pictured have HIV.